Nomogram for predicting disease recurrence after radical cystectomy for transitional cell carcinoma of the bladder

被引:184
作者
Karakiewicz, Pierre I.
Shariat, Shahrokh F.
Palapattu, Ganesh S.
Gilad, Amiel E.
Lotan, Yair
Rogers, Craig G.
Vazina, Amnon
Gupta, Amit
Bastian, Patrick J.
Perrotte, Paul
Sagalowsky, Arthur I.
Schoenberg, Mark
Lerner, Seth P.
机构
[1] Baylor Coll Med, Scott Dept Urol, Houston, TX 77030 USA
[2] Univ Montreal, Canc Prognost & Hlth Outcomes Unit, Montreal, PQ, Canada
[3] Univ Texas, SW Med Ctr, Dept Urol, Dallas, TX 75230 USA
[4] Johns Hopkins Univ Hosp, James Buchanan Brady Urol Inst, Baltimore, MD 21287 USA
关键词
bladder neoplasms; cystectomy; nomograms; recurrence; neoplasm staging;
D O I
10.1016/j.juro.2006.06.025
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 [临床医学]; 100201 [内科学];
摘要
Purpose: American Joint Committee on Cancer staging represents the gold standard for prediction of recurrence after radical cystectomy in patients with invasive bladder cancer. We tested the hypothesis that American Joint Committee on Cancer stage based predictions may be improved when pathological tumor and node stage information is combined with additional clinical and pathological variables within a prognostic nomogram. Materials and Methods: We used Cox proportional hazards regression analysis to model variables of 728 patients with transitional cell carcinoma of the bladder treated with radical cystectomy and bilateral pelvic lymphadenectomy at 1 of 3 participating institutions. Standard predictors, pT and pN, were complemented by age, gender, tumor grade at cystectomy, presence of lymphovascular invasion, presence of carcinoma in situ in the cystectomy specimen, neoadjuvant chemotherapy, adjuvant chemotherapy and adjuvant radiotherapy. The concordance index was used to quantify the accuracy of regression coefficient based nomograms. A total of 200 bootstrap resamples were used to reduce overfit bias and for internal validation. Calibration plots were used to graphically explore the performance characteristics of the multivariate nomogram. Results: Followup ranged from 0.1 to 183.4 months (median 24.9, mean 36.4). Recurrence was recorded in 249 (34.2%) patients with a median time to recurrence of 108 months (range 0.8 to 131.9). Actuarial recurrence-free probabilities were 69.6% (95% CI 65.8%-73.0%), 60.2% (55.8%-64.3%) and 52.9% (47.3%-58.1%) at 2, 5 and 8 years after cystectomy, respectively. Two-hundred bootstrap corrected predictive accuracy of American Joint Committee on Cancer stage based predictions was 0.748. Accuracy increased by 3.2% (0.780) when age, lymphovascular invasion, carcinoma in situ, neoadjuvant chemotherapy, adjuvant chemotherapy and adjuvant radiotherapy were added to pathological stage information and used within a nomogram. Conclusions: A nomogram predicting bladder cancer recurrence after cystectomy is 3.2% more accurate than American Joint Committee on Cancer stage based predictions. Moreover, a nomogram approach combines several advantages such as easy and precise estimation of individual recurrence probability at key points after cystectomy, which all patients deserve to know and all treating physicians need to know.
引用
收藏
页码:1354 / 1361
页数:8
相关论文
共 16 条
[1]
Abol-Enein H, 2003, LANCET, V361, P1927
[2]
American Joint Committee on Cancer, 2002, AJCC CANC STAGING MA, V6th, P335
[3]
ATKINSON AC, 1980, BIOMETRIKA, V67, P413, DOI 10.1093/biomet/67.2.413
[4]
BRADLEY E, 1993, MONOGRAPHS STAT APPL, P275
[5]
Validation of the postoperative nomogram for 12-year sarcoma-specific mortality [J].
Eilber, FC ;
Brennan, MF ;
Eilber, FR ;
Dry, SM ;
Singer, S ;
Kattan, MW .
CANCER, 2004, 101 (10) :2270-2275
[6]
GRAMBSCH PM, 1994, BIOMETRIKA, V81, P515
[7]
EVALUATING THE YIELD OF MEDICAL TESTS [J].
HARRELL, FE ;
CALIFF, RM ;
PRYOR, DB ;
LEE, KL ;
ROSATI, RA .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1982, 247 (18) :2543-2546
[8]
Harrell FE, 1996, STAT MED, V15, P361, DOI 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO
[9]
2-4
[10]
The addition of interleukin-6 soluble receptor and transforming growth factor beta, improves a preoperative nomogram for predicting biochemical progression in patients with clinically localized prostate cancer [J].
Kattan, MW ;
Shariat, SF ;
Andrews, B ;
Zhu, KC ;
Canto, E ;
Matsumoto, K ;
Muramoto, M ;
Scardino, PT ;
Ohori, M ;
Wheeler, TM ;
Slawin, KM .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (19) :3573-3579